South Korean drugmaker Celltrion Inc said on Friday patients treated with its experimental COVID-19 antibody drug in a small-size early-stage trial showed at least a 44% improvement in recovery time.
Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc's remdesivir.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback